Roche at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
Roche takes part in 5 sessions at TIDES Europe 2026 in Amsterdam. Its program centres on regulatory CMC for oligonucleotides and peptides, including a joint look with Novo Nordisk at global guidance for synthetic oligonucleotides and lessons from recent Phase 3 peptide filings. It also covers enzymatic ligation for making oligonucleotides and process control for MCSGP.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Roche Basel, Switzerland | |
Swiss pharmaceutical and diagnostics company with oligonucleotide and peptide programmes in its drug pipeline. | Chair Wed Nov 4 08:00–08:05 Talk Wed Nov 4 14:00–14:30 Enzymatic Ligation for the Production of Oligonucleotides Screening many ways to cut and rejoin siRNA strands with enzymes, then scaling the best one up for cleaner, higher-yield production. Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 10:45–11:15 MCSGP Process Control and Characterization Strategy Keeping a multi-column peptide purification system dependable by working out which settings must stay within range to hold purity steady at full scale. Talk Thu Nov 5 11:15–11:45 Regulatory Insights from Recent Global Phase 3 Peptide Filings What health authorities asked about manufacturing, quality control and delivery devices during recent late-stage applications for peptide drugs. |
Instantly find 20 buyers from Roche
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction